Молимо вас користите овај идентификатор за цитирање или овај линк до ове ставке: https://scidar.kg.ac.rs/handle/123456789/8904
Пун извештај метаподатака
Поље DC-а ВредностЈезик
dc.rights.licenseopenAccess-
dc.contributor.authorLukic R.-
dc.contributor.authorGajovic N.-
dc.contributor.authorJovanovic I.-
dc.contributor.authorJurisevic M.-
dc.contributor.authorMijailovic Z.-
dc.contributor.authorMaric V.-
dc.contributor.authorPopovska Jovicic, Biljana-
dc.contributor.authorArsenijevic, Nebojsa-
dc.date.accessioned2020-09-19T16:58:43Z-
dc.date.available2020-09-19T16:58:43Z-
dc.date.issued2017-
dc.identifier.issn0278-0240-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/8904-
dc.description.abstract© 2017 Ruzica Lukic et al. Hepatitis C virus infection (HCV), one of the greatest causes of liver disease, is a frequent complication in patients with end-stage renal disease (ESRD) on dialysis. ESRD is defined as decreased glomerular filtration and also accompanied by impaired function of the immune system. Galectin-3 is a β-galactoside-binding lectin, involved in various biological processes including pathogenesis of chronic renal disease. The aim of our study was to estimate disease severity in ESRD HCV+ patients and analyze the serum concentrations of IL-1β, IL-4, IL-23, and IL-6; anti-HCV antibodies; and galectin-3. Also, we attempted to determine potential correlation between galectin-3 level and parameters of disease severity ALT and AST. Our results showed decreased levels of ALT and AST (p=0.00), demonstrating less liver destruction in ESRD HCV+ patients in comparison to HCV+ patients. Increased levels of IL-6 (p=0.03) implicate a hepatoprotective role of IL-6 in these patients. Also, level of galectin-3 (p=0.00) in the serum of ESRD HCV+ patients was higher than that of HCV+ patients. This alteration was accompanied with negative correlation between galectin-3 and AST and ALT, respectively (p=0.029; p=0.033). The presence of increased systemic levels of IL-6 and Gal-3 in ESRD HCV+ patients may be an attempt to counteract or limit ongoing proinflammatory processes and to downregulate chronic inflammation, suggesting the new aspects of HCV infection in ESRD patients.-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.sourceDisease Markers-
dc.titlePotential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients-
dc.typearticle-
dc.identifier.doi10.1155/2017/6275987-
dc.identifier.scopus2-s2.0-85018802318-
Налази се у колекцијама:Faculty of Medical Sciences, Kragujevac

Број прегледа

1109

Број преузимања

37

Датотеке у овој ставци:
Датотека Опис ВеличинаФормат 
10.1155-2017-6275987.pdf1.63 MBAdobe PDFСличица
Погледајте


Ова ставка је заштићена лиценцом Креативне заједнице Creative Commons